Shattuck Labs, Inc.
NASDAQ:STTKBiotechnology
+$0.11 today
- Market cap
- $467.46M
- Beta
- 1.09
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$0.44
Volume 0.79M
Average 0.69M
STTK Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Shattuck Labs, Inc.NASDAQ: STTK
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin not reported for Q1 FY2026
Over 3 fiscal years it widened by 10754.8 pp.
Context
- Net margin widened in 2 of the last 3 fiscal years.
What to watch
Whether net margin reaches the consensus estimate from 6 analysts of -33519.1% for the fiscal year ending Dec 2026, down from -4880.9% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- —— QoQ
- Last fiscal yearDec 2025
- -4880.9%-3562.8 pp YoY
- LTMMar 2026
- -4987.4%-3454.4 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | -3562.8 pp | -28638.2 pp | -25075.4 pp |
| 3 years | +10754.8 pp | -16567.6 pp | -27322.4 pp |
| 5 years | -4285.8 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -4880.9%
- Year-over-year change
- -3562.8pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -4880.9% | -3562.8pp |
| FY2024 | 2024-12-31 | -1318.1% | +3950.3pp |
| FY2023 | 2023-12-31 | -5268.4% | +10367.3pp |
| FY2022 | 2022-12-31 | -15635.7% | -15485.9pp |
| FY2021 | 2021-12-31 | -149.8% | — |
Net Margin vs competitors
How STTK compares with its peers on the latest reported figures
- STTK's LTM Mar 2026 net margin of -4987.4% is the lowest of the 6 companies compared; the peer median is 10.7%.
- Its year-over-year change of -3454.4 pp is the lowest of 3, against a peer median of +47.5 pp.
- Over three fiscal years its change of +10754.8 pp compares with a peer median of +30422.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 4030.7% | — | — | |
| FY2025 | 32.0% | — | — | |
| LTM Mar 2026 | 10.7% | -5.6 pp | +13.6 pp | |
| LTM Sep 2026 | -58.2% | +100.6 pp | — | |
| LTM Mar 2026 | -1363.9% | — | +60832.1 pp | |
| LTM Mar 2026 | -4987.4% | -3454.4 pp | +10754.8 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
NBPNovaBridge Biosciences | FY2025 | — | — | — |
| Peer median (excluding STTK) | 10.7% | +47.5 pp | +30422.9 pp | |
Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 30.02M | 652K | 1.66M | 5.72M | 1M |
| Cost of Revenue | 1.38M | 82.2M | 4.04M | 4.89M | 0 |
| Gross Profit | 28.64M | (81.55M) | (2.39M) | 827K | 1M |
| Gross Margin | 95.4% | -12507.2% | -143.9% | 14.5% | 100.0% |
| Research & Development | 56.56M | 82.9M | 74.31M | 67.21M | 35.27M |
| Selling, General & Admin | 18.72M | 19.68M | 19.3M | 19.08M | 17.24M |
| Operating Expenses | 73.91M | 21.78M | 89.57M | 81.39M | 52.51M |
| Depreciation & Amortization | 1.38M | 3.07M | 4.04M | 3.83M | 3.69M |
| EBITDA | (43.59M) | (98.87M) | (83.26M) | (71.58M) | (45.12M) |
| EBITDA Margin | -145.2% | -15164.4% | -5024.5% | -1251.2% | -4512.1% |
| Operating Income | (45.27M) | (103.33M) | (91.96M) | (80.57M) | (51.51M) |
| Operating Margin | -150.8% | -15848.0% | -5549.6% | -1408.3% | -5150.8% |
| Interest Income | 625K | 1.59M | 4.67M | 5.17M | 2.7M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 295K | 1.38M | 4.66M | 5.16M | 2.7M |
| Income Before Tax | (44.97M) | (101.95M) | (87.3M) | (75.41M) | (48.81M) |
| Pre-Tax Margin | -149.8% | -15635.7% | -5268.4% | -1318.1% | -4880.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (44.97M) | (101.95M) | (87.3M) | (75.41M) | (48.81M) |
| Net Margin | -149.8% | -15635.7% | -5268.4% | -1318.1% | -4880.9% |
| EPS (Basic) | (1.07) | (2.41) | (2.05) | (1.49) | (0.70) |
| EPS (Diluted) | (1.07) | (2.41) | (2.05) | (1.49) | (0.70) |
| Weighted Avg Shares | 42.03M | 42.38M | 42.6M | 50.76M | 69.58M |
| Weighted Avg Shares (Diluted) | 42.03M | 42.38M | 42.6M | 50.76M | 69.58M |
Shattuck Labs, Inc.
NASDAQ:STTK
Intrinsic Alpha fair value
Locked
Current Price
$4.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.